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Introduction	  
The	  menopause	  is	  the	  stage	  in	  a	  woman's	  life	  when	  menstruation	  stops,	  permanently.	  It	  occurs	  with	  
the	  final	  menstrual	  period	  and	  is	  usually	  diagnosed	  clinically	  after	  12	  months	  of	  amenorrhoea	  (1).	  
Peri-­‐menopause	  ends	  12	  months	  after	  the	  last	  menstrual	  period.	  The	  post-­‐menopause	  begins	  when	  
a	  woman	  has	  not	  had	  a	  period	  for	  12	  consecutive	  months,	  and	  continues	  throughout	  her	  life	  (1).The	  
mean	  age	  of	  the	  natural	  menopause	  is	  52	  years	  (1),	  although	  this	  can	  vary	  between	  different	  ethnic	  
groups	  (2).	  
The	  menopause	  has	  many	  effects	  on	  women’s	  bodies:	  	  the	  most	  common	  symptoms	  being	  
vasomotor	  symptoms:	  hot	  flushes	  (flashes)	  and	  night	  sweats.	  Other	  symptoms	  include	  mood	  
changes,	  memory	  and	  concentration	  loss,	  urogenital	  atrophy,	  a	  lack	  of	  interest	  in	  sex,	  headaches,	  
and	  joint	  and	  muscle	  stiffness	  (1).	  The	  health	  related	  quality	  of	  life	  (HRQoL)	  of	  women	  experiencing	  
these	  symptoms	  may	  be	  severely	  affected	  (3).	  About	  80%	  of	  women	  experience	  menopausal	  
symptoms	  and	  of	  those	  45%	  find	  the	  symptoms	  distressing	  (4).	  Hot	  flushes	  occur	  for	  70-­‐80%	  of	  peri-­‐
menopausal	  women	  and	  are	  most	  common	  in	  the	  first	  year	  after	  the	  final	  menstrual	  period	  (5),	  with	  
25%	  of	  these	  women	  being	  severely	  affected.	  Hot	  flushes	  may	  resolve	  in	  2-­‐5	  years	  but	  the	  median	  
duration	  is	  7.2	  years	  and	  can	  be	  longer,	  persisting	  beyond	  the	  age	  of	  60	  	  (6).	  In	  a	  US	  study	  women	  
with	  daily	  vasomotor	  symptoms	  report	  	  7	  or	  more	  moderate	  to	  very	  severe	  vasomotor	  symptoms	  in	  
a	  typical	  day	  (7).	  Vaginal	  symptoms	  occur	  in	  up	  to	  30%	  of	  women	  in	  the	  peri-­‐menopausal	  period	  and	  
up	  to	  47%	  of	  women	  during	  the	  post-­‐menopausal	  period	  (7).	  Research	  shows	  that	  menopausal	  
symptoms	  affect	  women	  in	  the	  workforce:	  	  about	  half	  working	  women	  over	  the	  age	  of	  50	  found	  it	  
somewhat	  or	  fairly	  difficult	  to	  cope	  with	  their	  work	  because	  of	  menopausal	  symptoms	  and	  of	  those	  
about	  5%	  had	  severe	  and	  debilitating	  symptoms	  and	  were	  severely	  compromised	  in	  their	  ability	  to	  
work	  (8).	  In	  summary	  the	  menopause	  is	  not	  a	  trivial	  change	  of	  life	  for	  women.	  	  
Menopause	  symptoms	  may	  prompt	  a	  woman	  to	  consult	  a	  health	  professional.	  The	  National	  Institute	  
of	  Health	  and	  Care	  Excellence	  (NICE)	  in	  the	  United	  Kingdom	  (UK),	  has	  recently	  published	  a	  Clinical	  
Knowledge	  Summary	  (CKS)	  for	  the	  Menopause	  (1)	  based	  on	  the	  recently	  published	  (November	  2015)	  
Full	  Clinical	  Guideline	  NG23	  (9).	  These	  emphasise	  the	  need	  for	  open	  discussion	  of	  risks	  and	  benefits	  
of	  hormone	  replacement	  therapy	  (HRT)	  to	  manage	  symptoms	  and	  other	  approaches	  to	  menopause	  
management,	  such	  as	  lifestyle	  modification.	  	  
The	  NICE	  guidelines	  (9)	  indicate	  initial	  menopause	  management	  options	  depend	  on	  the	  timing	  of	  the	  
consultation,	  peri-­‐menopause	  or	  post-­‐menopause	  and	  whether	  the	  woman	  has	  her	  uterus	  or	  not.	  
NICE	  guidelines	  	  (9)	  suggest	  advice	  should	  cover	  evidence	  for	  the	  benefits	  of	  combined	  HRT	  in	  
controlling	  symptoms,	  along	  with	  likely	  health	  benefits	  (e.g.	  reduction	  in	  osteoporosis);	  	  the	  risks	  
associated	  with	  combined	  HRT	  (oral	  and	  transdermal)	  explained,	  using	  the	  risk-­‐benefit	  tables	  
provided	  in	  the	  NICE	  guidelines.	  If	  HRT	  is	  the	  chosen	  option,	  guidelines	  state	  cyclical	  combined	  HRT	  
should	  be	  used	  in	  peri-­‐menopausal	  women	  and	  continuous	  HRT	  should	  be	  used	  in	  post-­‐menopausal	  
women.	  	  
There	  can	  be	  unwelcome	  effects	  related	  to	  HRT,	  such	  as	  breast	  tenderness,	  vaginal	  bleeding	  or	  
spotting,	  fluid	  retention,	  leg	  cramps,	  nausea/sickness	  and	  headache/migraine.	  	  Differing	  symptoms	  
may	  relate	  to	  oestrogen	  or	  progestogen	  or	  both	  (1,9).	  However	  these	  side-­‐effects	  may	  settle	  after	  
the	  first	  three	  months	  and	  NICE	  guidelines	  advise	  the	  health	  professional	  to	  encourage	  the	  woman	  
to	  persist	  with	  treatment,	  but	  if	  these	  problems	  continue	  NICE	  guidelines	  (9)	  suggest	  switching	  mode	  
of	  administration	  (oral	  to	  transdermal	  for	  example),	  HRT	  type,	  or	  (relative)	  dosage	  of	  hormones.	  
(1)(9).	  HRT	  compliance	  is	  a	  crucial	  issue	  when	  treating	  post-­‐menopausal	  women,	  since	  the	  beneficial	  
effects	  of	  hormones	  may	  be	  reduced	  or	  lost	  if	  women	  do	  not	  adhere	  to	  treatment,	  so	  addressing	  the	  
short	  term	  side-­‐effects	  of	  HRT	  is	  important	  for	  improving	  compliance	  (10).	  
The	  purpose	  of	  the	  research	  presented	  here	  was	  to	  investigate	  rates	  of	  combined	  (cyclical	  or	  
continuous)	  HRT	  use	  and	  HRT	  patterns	  in	  UK	  general	  practice	  in	  women	  ≥45	  years	  to	  understand	  the	  
reality	  of	  menopause	  management	  with	  HRT,	  using	  routine,	  electronic	  observational	  data	  and	  postal	  
surveys.	  The	  specific	  objectives	  of	  this	  study	  were	  to:	  investigate	  the	  demographic	  and	  clinical	  
characteristics	  of	  women	  with	  a	  menopause	  diagnosis	  treated	  with	  HRT	  or	  not	  on	  HRT;	  drug	  therapy	  
patterns	  for	  the	  management	  of	  menopause	  following	  initial	  HRT	  use	  and	  reasons	  and	  outcomes	  
associated	  with	  discontinuation	  of	  HRT.	  	  
Methods	  
Study	  Design	  
The	  study	  consisted	  of	  two	  parts,	  a	  retrospective	  observational	  study	  using	  The	  Health	  Improvement	  
Network	  (THIN)	  database	  examining	  women’s	  characteristics	  and	  treatment	  patterns	  (database	  
study),	  and	  a	  survey	  via	  postal	  questionnaire	  exploring	  reasons	  and	  outcomes	  associated	  with	  
discontinuation	  of	  HRT	  (survey	  study).	  	  
Database	  Study	  
Data	  Source	  
The	  THIN	  database	  contains	  pseudonymised	  electronic	  primary	  care	  health	  records	  from	  UK	  general	  
practices  and	  as	  of	  May	  2015	  contained	  records	  from	  over	  14	  million	  patients,	  of	  which	  over	  3.43	  
million	  were	  actively	  registered	  from	  648	  general	  practices.	  The	  age	  and	  gender	  profile	  of	  the	  active	  
patient	  population	  in	  THIN	  has	  been	  shown	  to	  be	  comparable	  to	  the	  UK	  population	  (11,12).	  	  
Study	  Population	  
The	  study	  population	  comprised	  women	  >45	  years	  who	  first	  received	  an	  oestrogen	  and	  progestogen	  
containing	  hormone	  therapy	  (study-­‐HRT)	  between	  1st	  January	  2006	  and	  13th	  January	  20101.	  To	  
compare	  demographic	  and	  clinical	  characteristics,	  women	  treated	  with	  a	  study-­‐HRT	  were	  matched	  
1:1	  with	  women	  not	  treated	  with	  HRT,	  who	  were	  registered	  at	  the	  same	  practice,	  aged	  over	  45	  years	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 The HRT products that are the subject of this research are assumed to be indicated for management of 
menopause symptoms. 
and	  whose	  age	  was	  within	  ±	  2	  years	  of	  their	  matched	  subject.	  Index	  date	  was	  assigned	  as	  the	  date	  of	  
the	  first	  prescription	  of	  a	  study-­‐HRT.	  Untreated	  matched	  subjects	  were	  assigned	  the	  same	  index	  
date	  as	  their	  treated	  matched	  subject.	  	  
Subjects	  were	  required	  to	  have	  ≥12	  months	  of	  baseline	  data	  prior	  to	  index	  date	  and	  ≥24	  months	  of	  
follow-­‐up	  data	  from	  index	  date.	  Women	  were	  excluded	  if	  they	  had	  a	  history	  of	  hysterectomy	  or	  
breast	  or	  uterine	  cancer,	  were	  pregnant	  during	  the	  study	  period,	  or	  had	  reported	  breast	  pain	  or	  
bleeding	  in	  the	  12	  months	  prior	  to	  index	  date.	  	  
Study	  Variables	  
Treatment	  patterns	  examined	  included	  treatment	  duration,	  time	  between	  menopause	  diagnosis	  and	  
first	  prescription	  for	  a	  study-­‐HRT,	  and	  treatment	  changes.	  A	  treatment	  phase	  began	  at	  the	  first	  
prescription	  of	  the	  medication	  and	  ended	  at	  the	  estimated	  end	  date	  of	  the	  last	  prescription.	  
Prescriptions	  were	  included	  in	  a	  treatment	  phase	  if	  there	  was	  <14	  days	  between	  the	  estimated	  end	  
date	  of	  the	  previous	  prescription	  and	  the	  next	  prescription	  date.	  Treatment	  patterns	  investigated	  
include:	  first	  study-­‐HRT	  prescribed	  at	  index	  date,	  switching	  of	  study-­‐HRT,	  add-­‐on	  therapy	  to	  study-­‐
HRT,	  re-­‐start	  of	  study-­‐HRT	  and	  discontinuation	  of	  study-­‐HRT.	  	  
Error!	  Reference	  source	  not	  found.	  illustrates	  changes	  to	  first-­‐line	  therapy	  for	  the	  management	  of	  
menopause.	  A	  switch	  was	  defined	  as	  a	  therapy	  change	  after	  the	  end	  of	  a	  treatment	  phase,	  including	  
different	  study-­‐HRT,	  non-­‐study	  HRT	  and	  non-­‐HRT.	  Changes	  to	  route	  of	  administration	  or	  strength	  
were	  considered	  a	  switch	  for	  study-­‐HRTs.	  A	  prescription	  for	  another	  product	  (study-­‐HRTs,	  other	  non-­‐
study	  HRTs	  or	  non-­‐HRTs)	  within	  a	  treatment	  phase	  of	  a	  continuing	  therapy	  was	  considered	  an	  add-­‐
on	  therapy.	  Re-­‐start	  of	  therapy	  was	  defined	  as	  initiation	  of	  therapy	  after	  an	  interval	  of	  ≥6	  months	  
between	  treatment	  phases.	  Women	  with	  an	  interval	  of	  >6	  months	  between	  the	  end	  of	  the	  last	  
treatment	  phase	  and	  end	  of	  follow-­‐up	  were	  considered	  to	  have	  discontinued	  treatment.	  
Other	  study	  variables	  include	  demographic	  characteristics	  (age,	  smoking	  status,	  Townsend	  score),	  
menopause	  status	  (menopause	  diagnosis,	  time	  between	  diagnosis	  and	  treatment)	  and	  medical	  
conditions	  related	  to	  menopause	  recorded	  in	  the	  12	  months	  prior	  to	  index	  date,	  including	  sleep	  
problems,	  osteoporosis,	  low	  bone	  density,	  vulvar	  vaginal	  atrophy,	  vaginal	  dryness	  and	  depression.	  
Survey	  Study	  
Data	  Source	  
Surveys	  were	  obtained	  using	  THIN	  Additional	  Information	  Services	  (AIS)	  using	  the	  encrypted	  identity	  
of	  the	  practice	  and	  patients.	  THIN	  AIS	  deciphered	  the	  practice	  code	  and	  sent	  a	  list	  of	  pseudonymised	  
patient	  codes	  to	  the	  GP	  who	  sent	  the	  questionnaire	  to	  the	  women.	  Women	  returned	  their	  
completed	  questionnaire	  to	  their	  GP	  who	  removed	  any	  identifiable	  information	  before	  returning	  to	  
THIN	  AIS.	  Researchers	  were	  sent	  the	  questionnaire	  with	  the	  original	  pseudonymised	  patient	  ID	  to	  
allow	  linkage	  to	  information	  obtained	  from	  the	  database	  study.	  
Survey	  Subjects	  
Survey	  subjects	  were	  selected	  from	  those	  prescribed	  study-­‐HRT	  in	  the	  database	  study,	  were	  active	  in	  
THIN	  between	  September	  2012	  and	  June	  2013	  and	  had	  at	  least	  one	  prescription	  for	  a	  study-­‐HRT	  
during	  this	  period	  to	  capture	  women	  who	  were	  either	  still	  receiving	  HRT	  or	  just	  discontinued	  HRT	  
when	  the	  questionnaire	  was	  administered.	  	  Women	  were	  asked	  to	  consent	  to	  the	  study	  and	  whether	  
they	  were	  receiving	  HRT	  at	  the	  time	  of	  completion.	  Depending	  on	  the	  responses,	  survey	  subjects	  
were	  divided	  into	  two	  groups:	  currently	  taking	  HRT	  and	  discontinued	  HRT.	  
Survey	  Questionnaire	  
For	  women	  who	  discontinued	  HRT,	  reasons	  for	  discontinuation	  were	  further	  explored.	  Additionally,	  
HRQoL	  was	  assessed	  using	  the	  Menopause	  Rating	  Scale	  (MRS)	  which	  has	  been	  shown	  to	  be	  a	  reliable	  
way	  of	  measuring	  and	  comparing	  menopause	  related	  HRQoL	  (14).	  MRS	  scores	  are	  split	  into	  11	  
psychological,	  somato-­‐vegetative	  and	  urogenital	  symptoms	  with	  each	  rated	  between	  0	  and	  4	  
depending	  on	  severity,	  giving	  a	  total	  score	  ranging	  from	  0	  to	  44	  where	  a	  higher	  score	  indicates	  more	  
severe	  symptoms.	  	  
Data	  Analysis	  
The	  analysis	  was	  exploratory	  and	  comprised	  of	  descriptive	  statistics;	  categorical	  data	  were	  
summarised	  by	  number	  and	  percentage	  of	  women	  in	  each	  category,	  and	  continuous	  data	  were	  
summarised	  by	  number	  of	  women,	  mean,	  standard	  deviation	  (SD),	  median	  and	  lower	  and	  upper	  
quartiles.	  Baseline	  characteristics	  were	  compared	  using	  t-­‐tests	  (continuous	  variables)	  and	  chi-­‐square	  
tests	  (categorical	  variables).	  MRS	  scores	  were	  compared	  between	  survey	  subjects	  currently	  taking	  
HRT	  and	  those	  discontinuing	  HRT.	  Database	  analyses	  were	  conducted	  using	  SAS	  version	  9.3	  and	  SAS	  
Enterprise	  Guide	  version	  5.1	  and	  the	  surveys	  using	  SAS	  version	  9.4.	  	  
The	  study	  was	  conducted	  in	  accordance	  with	  legal	  and	  regulatory	  requirements,	  as	  well	  as	  with	  
scientific	  purpose,	  value	  and	  rigor.	  Ethical	  approval	  was	  granted	  by	  NRES	  Committee	  North	  East	  –	  
Country	  Durham	  and	  Tees	  Valley	  on	  12th	  May	  2012	  (reference	  12/NE/0212).	  	  
Results	  
Database	  Study	  
We	  identified	  8,968	  women	  >45	  years	  with	  a	  prescription	  for	  a	  study-­‐HRT	  between	  1st	  January	  2006	  
and	  13th	  January	  2010	  who	  met	  all	  inclusion	  and	  exclusion	  criteria.	  These	  were	  matched	  1:1	  on	  age	  
and	  GP	  practice	  with	  women	  not	  prescribed	  HRT	  generating	  a	  study	  population	  of	  17,936	  women.	  
Baseline	  characteristics	  can	  be	  found	  in	  Error!	  Reference	  source	  not	  found..	  More	  women	  in	  the	  
treated	  group	  were	  a	  past	  or	  current	  smoker	  than	  in	  the	  untreated	  group.	  Over	  four	  times	  the	  
number	  of	  women	  in	  the	  treated	  group	  had	  a	  menopause	  diagnosis	  than	  the	  untreated	  group.	  The	  
majority	  of	  women	  in	  the	  treated	  group	  had	  a	  menopause	  diagnosis	  recorded;	  however	  menopause	  
stage	  (peri	  or	  post)	  was	  relatively	  poorly	  recorded	  in	  both	  groups.	  There	  were	  significant	  differences	  
(p<0.05)	  in	  the	  pre-­‐specified	  co-­‐morbid	  conditions	  associated	  with	  menopause	  recorded	  in	  the	  12	  
months	  prior	  to	  index	  date,	  with	  women	  in	  the	  treated	  group	  more	  likely	  to	  have	  these	  conditions.	  
Among	  women	  with	  a	  menopause	  diagnosis,	  mean	  time	  between	  diagnosis	  and	  first	  study-­‐HRT	  was	  
513	  days	  (SD=947),	  but	  median	  time	  was	  around	  four	  weeks	  (Error!	  Reference	  source	  not	  found.).	  
Mean	  and	  median	  time	  on	  treatment	  were	  more	  consistent,	  at	  approximately	  14	  months.	  
Error!	  Reference	  source	  not	  found.	  shows	  the	  first	  study-­‐HRT	  product	  prescribed	  at	  index	  date.	  
Almost	  two	  thirds	  of	  women	  were	  prescribed	  an	  estradiol	  and	  norethisterone	  therapy	  at	  index	  date	  
followed	  by	  conjugated	  oestrogen	  and	  norgestrel	  (14.8%).	  Almost	  all	  women	  (95%)	  changed	  therapy	  
during	  the	  study	  (Error!	  Reference	  source	  not	  found.).	  Some	  women	  made	  more	  than	  one	  change	  to	  
their	  therapy,	  with	  the	  most	  popular	  change	  being	  to	  switch	  therapy.	  Among	  those	  switching,	  over	  
60%	  remained	  on	  some	  form	  of	  HRT	  (Error!	  Reference	  source	  not	  found.).	  Just	  under	  7%	  of	  women	  
switched	  administration	  route,	  and	  of	  these	  a	  switch	  to	  a	  patch	  was	  most	  common	  (51.4%),	  followed	  
by	  a	  switch	  to	  oral	  (42.9%)	  and	  then	  a	  switch	  to	  both	  oral	  plus	  patch	  (5.7%).	  	  
Survey	  Study	  
400	  questionnaires	  were	  sent	  to	  GPs	  with	  230	  of	  these	  forwarded	  to	  the	  women.	  116	  women	  
returned	  the	  questionnaire,	  consented	  to	  participate	  in	  the	  study	  and	  provided	  information	  about	  
their	  current	  HRT	  status	  and	  were	  included	  in	  the	  analysis.	  Of	  the	  116	  women,	  three	  quarters	  were	  
on	  HRT	  and	  a	  quarter	  had	  discontinued	  treatment.	  Demographic	  characteristics	  and	  menopause	  
status	  can	  be	  found	  in	  Error!	  Reference	  source	  not	  found..	  Women	  on	  HRT	  appear	  to	  be	  slightly	  
more	  affluent	  and	  are	  more	  likely	  to	  be	  current	  smokers	  than	  those	  who	  discontinued	  treatment,	  
although	  these	  differences	  were	  not	  formally	  tested.	  	  	  
There	  were	  noticeable	  differences	  in	  the	  severity	  of	  menopausal	  symptoms	  between	  women	  
currently	  taking	  HRT	  and	  those	  discontinuing	  HRT	  (Error!	  Reference	  source	  not	  found.).	  Women	  on	  
HRT	  had	  significantly	  lower	  scores	  for	  somato-­‐vegetative	  and	  urogenital	  symptoms	  and	  total	  MRS	  
score	  than	  those	  discontinuing	  HRT	  (all	  p<0.05).	  Women	  on	  HRT	  were	  also	  associated	  with	  a	  lower	  
score	  for	  psychological	  symptoms	  vs.	  those	  discontinuing	  HRT,	  although	  the	  difference	  was	  not	  
statistically	  significant	  (p=0.18).	  Among	  those	  discontinuing	  HRT,	  the	  main	  reasons	  for	  
discontinuation	  include	  being	  advised	  by	  a	  doctor	  or	  nurse	  to	  stop	  taking	  treatment,	  suffering	  side-­‐
effects	  or	  concern	  about	  potential	  side-­‐effects	  (Table	  4).	  Concern	  about	  potential	  breast	  cancer	  was	  
a	  reason	  for	  discontinuing	  HRT	  in	  about	  one	  fifth	  of	  discontinuing	  women	  (Error!	  Reference	  source	  
not	  found.).	  	  
Discussion	  
To	  our	  knowledge,	  this	  study	  is	  the	  first	  to	  use	  observational	  data	  linked	  to	  a	  survey	  to	  investigate	  
characteristics	  of	  women	  treated	  in	  general	  practice	  with	  combined	  (cyclical	  or	  continuous)	  HRT,	  
patterns	  of	  HRT	  therapy,	  and	  reasons	  and	  outcomes	  associated	  with	  discontinuation	  of	  HRT.	  The	  
survey	  findings	  provide	  valuable	  insights	  into	  the	  experiences	  of	  women,	  continuing	  or	  discontinuing	  
HRT	  during	  our	  study	  period.	  The	  findings	  reflect	  a	  period	  when	  primary	  care	  management	  of	  the	  
menopause	  was	  very	  likely	  influenced	  by	  results	  from	  the	  Women’s	  Health	  Initiative	  (2002)	  (15)	  and	  
the	  Million	  Women	  study	  (2002)(16).	  	  Despite	  limitations	  of	  using	  observational	  data,	  such	  as	  
absence	  of	  detailed	  coding	  and	  potential	  bias,	  this	  study	  has	  important	  strengths	  as	  it	  describes	  
patterns	  of	  HRT	  usual	  usage	  	  in	  general	  practice	  from	  2006	  up	  to	  2010,	  provides	  information	  on	  
women’s	  experiences	  with	  HRT	  and	  sheds	  light	  on	  how	  HRT	  was	  prescribed	  and	  taken	  in	  usual	  
practice	  compared	  with	  the	  recommendations	  of	  the	  new	  NICE	  guidelines	  on	  the	  management	  of	  
the	  menopause	  issued	  in	  late	  2015	  (9).	  	  	  
Our	  results	  show	  the	  time	  between	  menopause	  diagnosis	  in	  the	  GP	  record	  and	  treatment	  initiation	  
varied	  greatly	  with	  a	  median	  of	  4	  weeks	  and	  a	  mean	  of	  almost	  17	  months.	  Mean	  and	  median	  times	  
on	  HRT	  were,	  in	  general,	  consistent	  at	  just	  over	  a	  year.	  This	  duration	  is	  relatively	  short	  in	  contrast	  
with	  the	  new	  NICE	  guidance	  (1,9)	  which	  does	  not	  state	  a	  limit	  for	  the	  duration	  of	  HRT	  but	  suggests	  
women	  going	  through	  the	  menopause	  should	  have	  an	  annual	  review	  and	  only	  undertake	  a	  trial	  
withdrawal	  if	  they	  are	  symptom	  free	  after	  1-­‐2	  years	  on	  treatment.	  This	  recommendation	  is	  based	  on	  
the	  understanding	  that	  if	  symptoms	  return,	  HRT	  will	  be	  reinitiated,	  as	  vasomotor	  symptoms	  can	  
continue	  for	  many	  years	  (5).	  Our	  study	  also	  indicates	  almost	  all	  women	  treated	  with	  HRT	  in	  the	  
database	  study	  changed	  treatment	  during	  the	  follow	  up	  period.	  This	  is	  consistent	  with	  the	  new	  NICE	  
guideline	  advice	  (1,9)	  which	  suggests	  side-­‐effects	  may	  be	  managed	  by	  change	  of	  dose,	  type	  or	  
administration	  route	  of	  HRT.	  	  
Women	  remaining	  on	  HRT	  had	  lower	  MRS	  scores	  indicating	  less	  severe	  menopause	  symptoms	  and	  
therefore	  better	  HRQoL	  than	  those	  who	  had	  stopped	  treatment.	  The	  main	  reason	  given	  for	  stopping	  
treatment	  was	  stated	  to	  be	  on	  the	  advice	  of	  a	  doctor	  or	  nurse	  which	  could	  imply	  this	  was	  not	  a	  
shared	  decision.	  However,	  side-­‐effects	  and	  potential	  side-­‐effects	  were	  also	  common	  reasons	  for	  
stopping	  as	  was	  the	  perceived	  increased	  risk	  of	  breast	  cancer.	  	  
A	  factor	  that	  was,	  and	  perhaps	  still	  is,	  linked	  to	  women	  stopping	  (or	  not	  starting)	  HRT	  to	  manage	  
menopause	  symptoms	  was	  the	  publication	  of	  two	  large	  studies	  –	  the	  Women’s	  Health	  Initiative	  
(2002)	  (15)	  and	  the	  Million	  Women	  study	  (2002)	  (16).	  Reid	  and	  Magee	  (17)	  summarise	  the	  
limitations	  of	  these	  two	  studies,	  relative	  to	  the	  ‘younger	  newly	  menopausal	  women	  initiating	  HRT’,	  
who	  did	  not	  form	  the	  majority	  of	  women	  in	  these	  studies.	  After	  the	  studies	  were	  published,	  the	  
number	  of	  prescriptions	  for	  HRT	  almost	  halved	  in	  Canada	  (17)	  and	  decreased	  by	  80%	  in	  the	  UK	  (18).	  	  
They	  comment	  that	  in	  the	  years	  since	  these	  studies	  were	  published	  to	  the	  present	  day,	  many	  health	  
professionals	  were	  trained	  in	  an	  environment	  where	  ‘use	  of	  HRT	  is	  frowned	  upon’	  (17).	  The	  current	  
climate,	  reflected	  by	  the	  2015	  NICE	  guidance	  (1,9)	  emphasises	  the	  importance	  of	  HRT	  to	  manage	  the	  
symptoms	  of	  the	  menopause	  that	  cause	  an	  impact	  for	  an	  individual	  and	  promotes	  discussion	  about	  
the	  balance	  between	  the	  benefits	  and	  risks	  of	  HRT.	  The	  potential	  for	  management	  of	  side-­‐effects	  of	  
HRT,	  persisting	  with	  treatment	  or	  switching	  to	  different	  doses	  and	  methods	  of	  administration	  to	  
obtain	  symptom	  relief,	  with	  full	  discussion	  of	  risks	  and	  benefits	  relating	  to	  the	  individual	  woman,	  the	  
frequency	  and	  impact	  of	  symptoms	  and	  promoting	  annual	  review	  of	  menopause	  management	  is	  
reflected	  in	  current	  NICE	  guidance	  (1,9).	  
There	  were	  some	  limitations	  of	  this	  study:	  our	  survey	  sample	  was	  relatively	  small,	  including	  116	  
respondents	  out	  of	  the	  230	  who	  were	  sent	  surveys.	  The	  survey	  sample	  was	  dominated	  by	  people	  
who	  were	  continuing	  HRT.	  These	  respondents	  could	  be	  a	  biased	  sample;	  they	  were	  perhaps	  
motivated	  to	  respond	  because	  HRT	  was	  perceived	  to	  be	  a	  ‘successful	  treatment’	  for	  them.	  	  We	  
originally	  sent	  400	  surveys	  to	  GPs	  who	  were	  asked	  to	  give	  the	  surveys	  to	  eligible	  survey	  subjects.	  But	  
170	  surveys	  were	  not	  forwarded	  by	  some	  GPs	  for	  unknown	  reasons	  and	  we	  could	  not	  identify	  the	  
GPs	  who	  did	  not	  forward	  the	  surveys	  due	  to	  the	  anonymous	  nature	  of	  the	  survey	  –	  another	  factor	  
that	  may	  contribute	  to	  bias.	  	  	  The	  stage	  of	  the	  menopause	  (e.g.	  peri-­‐menopause	  or	  post-­‐menopause)	  
was	  poorly	  recorded	  in	  women	  treated	  or	  not	  treated	  with	  study-­‐HRT.	  This	  may	  be	  due	  to	  poor	  
recording	  in	  the	  database	  or	  may	  reflect	  a	  lack	  of	  distinction	  by	  the	  GP.	  Since	  the	  menopause	  stage	  
may	  impact	  prescribing	  decisions	  (cyclical	  or	  combined	  HRT)	  it	  is	  important	  to	  have	  made	  the	  
distinction	  and	  prescribe	  appropriately.	  This	  could	  be	  a	  focus	  for	  further	  research.	  Another	  limitation	  
is	  that	  we	  only	  know	  when	  a	  woman	  was	  diagnosed,	  not	  when	  menopause	  symptoms	  started.	  
Consequently,	  the	  time	  between	  diagnosis	  and	  treatment	  may	  be	  different	  from	  the	  amount	  of	  time	  
a	  woman	  experienced	  menopausal	  symptoms.	  Future	  research	  to	  measure	  time	  from	  onset	  of	  
symptoms	  to	  treatment	  initiation	  would	  be	  informative.	  Finally,	  prescribing	  decision	  may	  be	  
influenced	  by	  	  	  aspects	  other	  than	  a	  diagnosis,	  and	  these	  factors	  may	  not	  be	  captured	  in	  routine	  
data.	  We	  do	  not	  know	  all	  the	  factors	  that	  may	  have	  influenced	  a	  decision	  to	  initiate	  HRT	  and	  
decisions	  to	  discontinue	  or	  continue	  HRT.	  
In	  summary,	  in	  our	  general	  practice	  study	  population	  and	  over	  the	  study	  period,	  duration	  of	  HRT	  was	  
just	  over	  one	  year,	  relatively	  short	  compared	  to	  current	  NICE	  recommendations	  (1,9).	  About	  95%	  of	  
women	  switched	  HRT	  during	  the	  their	  course	  of	  treatment	  which	  is	  more	  consistent	  with	  NICE	  
advice	  on	  how	  to	  manage	  side-­‐effects	  of	  HRT(1,9).	  Women	  continuing	  on	  HRT	  experienced	  less	  
severe	  menopause	  symptoms	  compared	  with	  those	  discontinuing	  treatment.	  Advice	  from	  health	  
professionals	  and	  concerns	  about	  side-­‐effects	  were	  among	  major	  reasons	  for	  discontinuation	  of	  
HRT.	  	  
Looking	  to	  the	  future,	  in	  the	  context	  of	  new	  NICE	  guidance	  and	  reflecting	  on	  our	  study	  findings,	  it	  is	  
important	  to	  encourage	  dialogue	  between	  women	  and	  health	  professionals	  to	  enable	  informed	  
choices	  to	  be	  made	  concerning	  using	  HRT,	  to	  aid	  the	  menopause	  transition.	  Future	  research	  using	  
routine,	  medical	  records	  data	  to	  explore	  the	  impact	  of	  the	  2015	  
	  
	  NICE	  menopause	  guidance	  (9)	  on	  HRT	  use	  in	  general	  practice	  is	  warranted	  in	  order	  to	  establish	  
whether	  guidelines	  are	  being	  implemented.	  	  
References	  	  
1.	  	   National	  Collaborating	  Centre	  for	  Women	  and	  Child	  Health.	  Menopause:	  Clinical	  Knowledge	  
Summary.	  London	  UK;	  2015.	  	  
2.	  	   Williams	  RE,	  Kalilani	  L,	  DiBenedetti	  DB,	  Zhou	  X,	  Granger	  AL,	  Fehnel	  SE,	  et	  al.	  Frequency	  and	  
severity	  of	  vasomotor	  symptoms	  among	  peri-­‐	  and	  postmenopausal	  women	  in	  the	  United	  States.	  
Climacteric.	  United	  States;	  2008	  Feb;11(1):32–43.	  	  
3.	  	   Freedman	  MA.	  Quality	  of	  life	  and	  menopause:	  the	  role	  of	  estrogen.	  J	  Womens	  Health	  
(Larchmt).	  United	  States;	  2002	  Oct;11(8):703–18.	  	  
4.	  	   Royal	  College	  of	  Physicians	  Edinburgh	  .	  Consensus	  Conference	  on	  Hormone	  Replacement	  
Therapy:	  Final	  Consensus	  Statement.	  Edinburgh;	  2003.	  	  
5.	  	   Rees,	  M.,	  Stevenson,	  J.,	  Hope,	  S.	  &	  Al	  E.	  Management	  of	  the	  Menopause:	  the	  Handbook.	  
London/Marlow:	  Royal	  Society	  of	  Medicine	  Press	  Ltd.	  &	  British	  Menopause	  Society;	  2009.	  	  
6.	  	   Avis	  NE,	  Crawford	  SL,	  Greendale	  G,	  Bromberger	  JT,	  Everson-­‐Rose	  SA,	  Gold	  EB,	  et	  al.	  Duration	  
of	  menopausal	  vasomotor	  symptoms	  over	  the	  menopause	  transition.	  JAMA	  Intern	  Med.	  United	  
States;	  2015	  Apr;175(4):531–9.	  	  
7.	  	   Grady	  D.	  Management	  of	  Menopausal	  Symptoms.	  N	  Engl	  J	  Med	  [Internet].	  Massachusetts	  
Medical	  Society;	  2006	  Nov	  30;355(22):2338–47.	  Available	  from:	  
http://dx.doi.org/10.1056/NEJMcp054015	  
8.	  	   Kopenhager	  T,	  Guidozzi	  F.	  Working	  women	  and	  the	  menopause.	  Climacteric.	  England;	  2015	  
Jun;18(3):372–5.	  	  
9.	  	   NICE.	  Menopause:	  Full	  Clinical	  Guidance.	  London	  UK;	  2015.	  	  
10.	  	   Shmuely	  Y,	  Berlin	  JA,	  Knauss	  J,	  Lydick	  E.	  Compliance	  with	  oral	  HRT	  in	  postmenopausal	  
women	  in	  clinical	  trials-­‐-­‐meta	  analysis.	  Maturitas.	  Ireland;	  2003	  Sep;46(1):33–44.	  	  
11.	  	   Blak	  BT,	  Thompson	  M,	  Dattani	  H,	  Bourke	  A.	  Generalisability	  of	  The	  Health	  Improvement	  
Network	  (THIN)	  database:	  demographics,	  chronic	  disease	  prevalence	  and	  mortality	  rates.	  Inform	  
Prim	  Care.	  England;	  2011;19(4):251–5.	  	  
12.	  	   Blak	  BT,	  Thompson	  M.	  How	  does	  The	  Health	  Improvement	  Network	  (THIN)	  data	  on	  
prevalence	  of	  chronic	  dieseases	  compare	  with	  national	  figures?	  Value	  Heal	  [Internet].	  Elsevier;	  2015	  
Nov	  17;12(7):A253.	  Available	  from:	  http://dx.doi.org/10.1016/S1098-­‐3015(10)74240-­‐6	  
13.	  	   Maguire	  A,	  Blak	  BT,	  Thompson	  M.	  The	  importance	  of	  defining	  periods	  of	  complete	  mortality	  
reporting	  for	  research	  using	  automated	  data	  from	  primary	  care.	  Pharmacoepidemiol	  Drug	  Saf.	  
England;	  2009	  Jan;18(1):76–83.	  	  
14.	  	   Heinemann	  K,	  Ruebig	  A,	  Potthoff	  P,	  Schneider	  HPG,	  Strelow	  F,	  Heinemann	  LAJ,	  et	  al.	  The	  
Menopause	  Rating	  Scale	  (MRS)	  scale:	  a	  methodological	  review.	  Health	  Qual	  Life	  Outcomes.	  England;	  
2004;2:45.	  	  
15.	   Writing	  Group	  for	  the	  Women's	  Health	  Initiative	  I.	  Risks	  and	  benefits	  of	  estrogen	  plus	  
progestin	  in	  healthy	  postmenopausal	  women:	  Principal	  results	  from	  the	  women&#39;s	  health	  
initiative	  randomized	  controlled	  trial.	  Jama.	  2002;288(3):321-­‐33.	  
16.	   Million	  Women	  Study	  CollaboratorsThe	  collaborators	  are	  listed	  on	  p.	  Patterns	  of	  use	  of	  
hormone	  replacement	  therapy	  in	  one	  million	  women	  in	  Britain,	  1996–2000.	  BJOG:	  An	  International	  
Journal	  of	  Obstetrics	  and	  Gynaecology.	  2002;109(12):1319-­‐30.	  
17.	  	   Reid	  RL,	  Magee	  BA.	  Confronting	  the	  challenges	  of	  the	  menopausal	  transition.	  Women’s	  
Midlife	  Heal	  [Internet].	  2015;1(1):1–9.	  Available	  from:	  http://dx.doi.org/10.1186/s40695-­‐015-­‐0008-­‐5	  
18.	  	   Burger	  HG,	  MacLennan	  AH,	  Huang	  K-­‐E,	  Castelo-­‐Branco	  C.	  Evidence-­‐based	  assessment	  of	  the	  
impact	  of	  the	  WHI	  on	  women’s	  health.	  Climacteric.	  England;	  2012	  Jun;15(3):281–7.	  	  
	  
	  
	   	  
Tables	  
Table	  1.   Women  characteristics  at  index  date  by  HRT  status.    





N	   8,968	   8,968	   	  
Age	  at	  index	  date	  (years)	   	   	   	  
Mean	  (SD)	   50.5	  (4.2)	   50.5	  (4.3)	  
0.806	  
Median	  (IQR)	   50.0	  (48.0	  –	  52.0)	   50.0	  (47.0	  –	  53.0)	  
Age	  at	  menopause	  diagnosis	  (years)*	   	   	   	  
Mean	  (SD)	   49.2	  (4.0)	   48.5	  (4.4)	  
<0.001	  
Median	  (IQR)	   49.0	  (47.0	  –	  51.0)	   49.0	  (46.0	  –	  51.0)	  
Smoking	  status,	  n	  (%)**	   	   	   	  
Current	  smoker	   2,087	  (23.6)	   1,641	  (19.1)	  
<0.001	  
Past	  smoker	   2,245	  (25.4)	   1,666	  (19.4)	  
Never	  smoker	   4,524	  (51.1)	   5,286	  (61.5)	  
Unknown	   112	   375	  
Townsend	  score,	  n	  (%)**	   	   	   	  
1	  (most	  affluent)	   2,618	  (30.3)	   2,670	  (30.7)	  
0.274	  
2	   2,096	  (24.2)	   2,170	  (24.9)	  
3	   1,720	  (19.9)	   1,722	  (19.8)	  
4	   1,385	  (16.0)	   1,291	  (14.8)	  
5	  (least	  affluent)	   835	  (9.7)	   853	  (9.8)	  
Unknown	   314	   262	   	  
Menopause	  diagnosis,	  n	  (%)	   	   	   	  
Any	  type	  recorded	   7,664	  (85.5)	   1,636	  (18.2)	   <0.001	  
Peri-­‐menopause	  specified	   948	  (10.6)	   241	  (2.7)	   <0.001	  
Post-­‐menopause	  specified	   584	  (6.5)	   249	  (2.8)	   <0.001	  
Co-­‐morbid	  conditions	  recorded	  in	  the	  12	  
months	  prior	  to	  index	  date	  	  
	   	   	  
Sleep	  problems	   211	  (2.4)	   77	  (0.9)	   <0.001	  
Osteoporosis	   37	  (0.4)	   17	  (0.2)	   0.006	  
Low	  bone	  density	   10	  (0.1)	   1	  (0.0)	   0.007	  
Vulvar	  vaginal	  atrophy	   77	  (0.9)	   17	  (0.2)	   <0.001	  
Vaginal	  dryness	   37	  (0.4)	   12	  (0.1)	   <0.001	  
Depression	   789	  (8.8)	   345	  (3.9)	   <0.001	  
*	  Age	  at	  the	  time	  of	  menopause	  diagnosis	  is	  not	  necessarily	  the	  age	  menopause	  began	  
**	  Percentages	  displayed	  are	  of	  non-­‐missing	  values	  
	  
Table	  2.   Days  between  menopause  diagnosis  and  HRT  initiation  and  duration  of  HRT    
	   Mean	   Standard	   Median	   Quartiles	  
	   Deviation	   	   Lower	   Upper	  
Days	  between	  diagnosis	  and	  HRT	  
treatment	  (N=7,022)*	  
513.1	   947.4	   28.0	   0.0	   662.0	  
Duration	  of	  HRT	  (days)	  	  
(N=8,968)	  
432.4	   317.7	   420.0	   84.0	   756.0	  
*1,946	  women	  excluded	  as	  1,304	  did	  not	  have	  a	  menopause	  diagnosis	  and	  642	  had	  a	  diagnosis	  after	  
their	  first	  study-­‐HRT	  prescription.	  	  
	   	  
Table	  3.   Characteristics  of  women  completing  survey  questionnaire  by  discontinuation  
status  (N=116)*  
	   Currently	  taking	  
study-­‐HRT	  
Discontinued	  	  HRT	  
N	   89	   27	  
Age	  at	  index	  date	  (years)	   	   	  
Mean	  (SD)	   49.5	  (3.4)	   49.4	  (3.8)	  
Median	  (IQR)	   49.0	  (47.0	  –	  52.0)	   49.0	  (46.0	  –	  51.0)	  
Age	  at	  menopause	  diagnosis	  (years)**	   	   	  
Mean	  (SD)	   48.6	  (3.6)	   48.3	  (3.7)	  
Median	  (IQR)	   48.0	  (46.0	  –	  51.0)	   48.5	  (46.0	  –	  51.0)	  
Smoking	  status,	  n	  (%)***	   	   	  
Current	  smoker	   18	  (20)	   2	  (7)	  
Past	  smoker	   22	  (25)	   13	  (48)	  
Never	  smoker	   49	  (55)	   12	  (44)	  
Unknown	   0	   0	  
Region,	  n	  (%)	   	   	  
England	   67	  (75)	   21	  (78)	  
Wales	   3	  (3)	   3	  (11)	  
Scotland	   16	  (18)	   3	  (11)	  
Northern	  Ireland	   3	  (3)	   0	  (0)	  
Townsend	  score,	  n	  (%)***	   	   	  
1	  (most	  affluent)	   27	  (31)	   8	  (30)	  
2	   26	  (30)	   7	  (26)	  
3	   15	  (17)	   4	  (15)	  
4	   14	  (16)	   4	  (15)	  
5	  (least	  affluent)	   4	  (5)	   4	  (15)	  
Unknown	   3	   0	  
Menopause	  diagnosis,	  n	  (%)	   	   	  
Any	  type	  recorded	   77	  (87)	   24	  (89)	  
Peri-­‐menopause	  specified	   11	  (12)	   3	  (11)	  
Post-­‐menopause	  specified	   6	  (7)	   1	  (4)	  
*	  Demographics	  found	  by	  linking	  women	  surveys	  to	  database	  data	  using	  pseudonymised	  women	  ID.	  	  
**	  Age	  at	  the	  time	  of	  menopause	  diagnosis	  is	  not	  necessarily	  the	  age	  menopause	  began	  
***	  Percentages	  displayed	  are	  of	  non-­‐missing	  values	  
	  
	   	  
Table	  4.   Reasons  for  discontinuation  of  HRT  (N=27)  
Reason	  for	  discontinuation	  of	  HRT	   n	  (%)	  
N	  
	  The	  medication	  did	  not	  adequately	  relieve	  my	  menopausal	  symptoms	   1	  (4)	  
The	  prescription	  charge	  was	  too	  high	   1	  (4)	  
My	  menopausal	  symptoms	  improved	   7	  (26)	  
I	  gained	  weight	   4	  (15)	  
The	  side-­‐effects	  bothered	  me	   9	  (33)	  
Breast	  tenderness/pain	   3	  (11)	  
Vaginal	  bleeding/spotting	   3	  (11)	  
Swelling	  of	  the	  hands,	  arms,	  feet,	  ankles,	  or	  legs	   0	  (0)	  
Feeling	  sick/nausea	   1	  (4)	  
Headache/migraine	   3	  (11)	  
Other	   5	  (19)	  
I	  was	  concerned	  it	  might	  cause	  health	  problems	   8	  (30)	  
Breast	  cancer	   6	  (22)	  
Cancer	  of	  the	  uterus/womb	   3	  (11)	  
Weight	  gain	   2	  (7)	  
Blood	  clots	   2	  (7)	  
Stroke/heart	  disease	   2	  (7)	  
Other	   2	  (7)	  
My	  doctor/nurse	  advised	  me	  to	  stop	  taking	  HRT	  because	  they	  felt	  I	  no	  longer	  needed	  it	   11	  (41)	  
Other	  reasons	   14	  (52)	  
	  
	   	  
Figures	  
Figure	  1.   Treatment  phases  including  first  line  therapy,  switch,  add-­on,  re-­start  and  
discontinuation  
	  
Figure	  2.   First  study-­HRT  prescribed  at  index  date  (N=8,968)  
	  
	  
	   	  
Estradiol	  and	  norethisterone	  -­‐ 64.9%
Conjugated	  oestrogen	  and	  norgestrel	  -­‐ 14.8%
Estradiol	  and	  dydrogesterone	  -­‐ 7.5%
Estradiol	  and	  levonorgestrel	  -­‐ 4.3%
Conjugated	  oestrogen	  and	  medroxyprogesterone	  -­‐ 3.8%
Estradiol	  and	  medroxyprogesterone	  -­‐ 2.3%
Estradiol	  and	  norgestrel	  -­‐ 1.8%
Estradiol	  and	  drospirenone	  -­‐ 0.5%
Ethinylestradiol	  and	  norelgestromin	  -­‐ 0.1%




Figure	  4.   Overall  patterns  of  first  switch  for  women  treated  with  study-­HRT  and  























Therapy	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  not	  
change










Figure	  5.   Mean  Menopause  Rating  Scale  (MRS)  score  by  discontinuation  status  
(N=102  women  completing  all  parts  of  MRS  question)  
*	  Psychological	  symptoms	  include	  depressed,	  irritable,	  anxious,	  exhausted	  (0	  –	  16	  points)	  
**	  Somato-­‐vegetative	  symptoms	  include	  sweating/flush,	  cardiac	  complaints,	  sleeping	  disorders,	  joint	  
&	  muscle	  complaints	  (0	  –	  16	  points)	  



















Currently	  taking	  HRT	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  HRT
